These results showed that CMV may improve the polyfunctionality and consequently the quality of global CD8+ T cell immune response, CMV-specific immunity and newly-generated immune response against leukemia like WT1 in the context of allo-HSCT, although we found no evidence for any antigen-specific differences. The gene discussed is CD8A; the disease is leukemia.